After some very public cajoling, executives from some of the world’s largest drug makers have now agreed to testify about drug pricing at a Senate hearing later this month.
Of course, they would be foolish not to do so. The Senate Finance Committee leadership is not especially friendly to the pharmaceutical industry, which is already under siege. Showing up is simply smart politics in the face of proposals and legislation that could change the way they do business.
After all, President Trump publicly berated Pfizer last year for taking a big round of price hikes and none of these executives need that kind of aggravation. And momentum is obviously building in Washington to do something about pricing. Now is not the time to appear indifferent or even mildly uncooperative.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.